Early-Stage Induction of SWI/SNF Mutations during Esophageal Squamous Cell Carcinogenesis

Hidetsugu Nakazato1,2,3, Hideyuki Takeshima1, Takayoshi Kishino1, Emi Kubo1, Naoko Hattori1, Takeshi Nakajima4, Satoshi Yamashita1, Hiroyasu Igaki2, Yuji Tachimori2, Yukio Kuniyoshi3, Toshikazu Ushijima1

1 Division of Epigenomics, National Cancer Center Research Institute, Tokyo, Japan, 2 Esophageal Surgery Division, National Cancer Center Hospital, Tokyo, Japan, 3 Department of Thoracic and Cardiovascular Surgery, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan, 4 Endoscopy Division, National Cancer Center Hospital, Tokyo, Japan

* tushijim@ncc.go.jp

Abstract

The SWI/SNF chromatin remodeling complex is frequently inactivated by somatic mutations of its various components in various types of cancers, and also by aberrant DNA methylation. However, its somatic mutations and aberrant methylation in esophageal squamous cell carcinomas (ESCCs) have not been fully analyzed. In this study, we aimed to clarify in ESCC, what components of the SWI/SNF complex have somatic mutations and aberrant methylation, and when somatic mutations of the SWI/SNF complex occur. Deep sequencing of components of the SWI/SNF complex using a bench-top next generation sequencer revealed that eight of 92 ESCCs (8.7%) had 11 somatic mutations of 7 genes, ARID1A, ARID2, ATRX, PBRM1, SMARCA4, SMARCAL1, and SMARCC1. The SMARCA4 mutations were located in the Forkhead (85Ser>Leu) and SNF2 family N-terminal (882Glu>Lys) domains. The PBRM1 mutations were located in a bromodomain (80Asn>Ser) and an HMG-box domain (1,377Glu>Lys). For most mutations, their mutant allele frequency was 31–77% (mean 61%) of the fraction of cancer cells in the same samples, indicating that most of the cancer cells in individual ESCC samples had the SWI/SNF mutations on one allele, when present. In addition, a BeadChip array analysis revealed that a component of the SWI/SNF complex, ACTL6B, had aberrant methylation at its promoter CpG island in 18 of 52 ESCCs (34.6%). These results showed that genetic and epigenetic alterations of the SWI/SNF complex are present in ESCCs, and suggested that genetic alterations are induced at an early stage of esophageal squamous cell carcinogenesis.
components of the SWI/SNF complex are frequently mutated in various types of cancers. *ARID1A* is frequently mutated in ovarian clear cell carcinomas [9, 10], hepatocellular carcinomas (HCCs) [11, 12], and gastric cancers [4, 6, 13]; *ARID2* in HCCs [11, 12, 14]; *PBRM1* in renal cell carcinomas [15]; and *SMARCA4* in small cell carcinomas of the ovary of hypercalcemic type (SCCOHT) [16–18]. As for esophageal squamous cell carcinomas (ESCCs), somatic mutations have been detected for *ARID1A, ARID2,* and *PBRM1* by exome-sequencing [3].

The components of the SWI/SNF complex are also inactivated by aberrant DNA methylation of promoter CpG islands [13, 19], which is known to be involved in the repression of gene transcription. Components of the SWI/SNF complex, *ACTL6B, SMARCA2,* and *SMARCD3,* and those of the other types of chromatin remodeling complex, *ATRX* and *SMARCA1,* are aberrantly methylated in gastric cancers [18]; *ARID1A* in invasive breast cancers [19]; *ARID1B* in pancreatic cancers [20], and *ACTL6B* in hepatocellular carcinomas (HCCs) [21]. However, the presence of aberrant methylation of the components of the SWI/SNF complex in ESCCs is still unclear.

In this study, we aimed to clarify, in ESCC, 1) what components of the SWI/SNF complex have somatic mutations by deep sequencing using a bench-top next generation sequencer to overcome the intrinsic limitation in the reading depth of exome-sequencing, 2) what components have aberrant methylation, and 3) when somatic mutations of the SWI/SNF complex occur. It was found that genetic and epigenetic alterations of the SWI/SNF complex are present in ESCCs, and it was suggested that genetic alterations are induced at an early stage of esophageal squamous cell carcinogenesis.

### Materials and Methods

#### 2.1 Clinical samples

Ninety-two primary ESCC samples and their corresponding non-cancerous tissue samples were endoscopically collected from ESCC patients with written informed consents. The collected samples were stored in RNAlater (Life Technologies, Carlsbad, CA, USA) at -80°C until the extraction of genomic DNA. Clinical information of the 92 ESCCs is listed in Table 1. The study was approved by the Institutional Review Boards of the National Cancer Center. Genomic DNA was extracted from ESCC samples by the standard phenol/chloroform method, and was quantified using a Quant-iT PicoGreen dsDNA Assay Kit (Life Technologies).

#### 2.2 Cell lines

Nine human ESCC cell lines, KYSE30, KYSE140, KYSE170, KYSE180, KYSE220, KYSE270, KYSE410, KYSE450, and KYSE510, were obtained from the Japanese Collection of Research Bioresources (JCRB) Cell Bank [22]. Two neuroblastoma cell lines, IMR-32 and KELLY, were obtained from the JCRB Cell Bank and Public Health England, respectively. KYSE140 was cultured in Ham’s F12 medium containing 2% (v/v) FBS; KYSE30, KYSE170, KYSE180, KYSE220, KYSE270, KYSE410, KYSE450, and KYSE510 were cultured in Ham’s F12/RPMI1640 medium containing 2% (v/v) FBS; IMR-32 was cultured in MEM medium containing 10% (v/v) FBS and non-essential amino acid (NEAA); and KELLY was cultured in RPMI1640 medium containing 10% (v/v) FBS.

#### 2.3 Analysis of somatic mutations

Mutation analysis of 18 genes encoding components of the SWI/SNF complex was conducted as described previously [13]. Briefly, a DNA library containing 672 kinds of DNA fragments covering 86.5–100% (mean 96.9%) of the coding regions of the 18 genes (*ACTL6A, ACTL6B,*
ARID1A, ARID1B, ARID2, ATRX, PBRM1, PHF10, SMARCA1, SMARCA2, SMARCA4, SMARCAL1, SMARCB1, SMARCC1, SMARCC2, SMARCD1, SMARCD3, and SMARCE1) was prepared by multiplex PCR. A DNA library prepared from an ESCC sample was uniquely barcoded, and sequencing was conducted using an Ion Proton Sequencer (Life Technologies). The sequences obtained were mapped onto the human reference genome (hg19). Somatic mutations in individual ESCC samples were identified by subtraction of the sequence variations also detected in the corresponding non-cancerous tissue of the cancer sample. Somatic mutations identified using the Ion Proton Sequencer were confirmed by Sanger sequencing of amplified DNA using the primers listed in S1 Table. As for mutations with a low frequency, amplified DNA was cloned into pGEM-T Easy vector (Promega, Madison, WI, USA), and sequences were confirmed by analysis of 10 pools of four clones (40 clones).

2.4 Analysis of DNA methylation

DNA methylation data of primary ESCCs and ESCC cell lines were obtained using an Infinium HumanMethylation450 BeadChip array (Illumina, San Diego, CA), which covered 482,421 CpG sites in a previous study (GSE74693) [23]. Among various CpG sites, only those in TSS200 [a region between transcription start site (TSS) and its 200 bp upstream] or 1st exon/5'-UTR with CpG islands were analyzed for ACTL6A, ACTL6B, ARID1A, ARID2, PBRM1, SMARCA2, SMARCA4, SMARCAL1, SMARCB1, SMARCC1, SMARCC2, SMARCD1, SMARCD3, and SMARCE1 as described previously [13]. DNA methylation was assessed using β values, and genes were defined as unmethylated (β value, 0–0.2), partially methylated (β value, 0.2–0.4 for primary ESCCs and 0.2–0.8 for ESCC cell lines), and methylated (β value, 0.4–1.0 for primary ESCCs and 0.8–1.0 for ESCC cell lines).

| Characteristics | Categories | No. of patients |
|-----------------|-----------|----------------|
| Total           |           | 92             |
| Age             | 30–79 (average, 64.3) |
| Sex             | Male      | 79             |
|                 | Female    | 13             |
| Tumor site      | Upper     | 11             |
|                 | Middle    | 55             |
|                 | Lower     | 26             |
| Histology       | SCC       | 92             |
| Clinical T stage| T1a       | 2              |
|                 | T1b       | 22             |
|                 | T2        | 11             |
|                 | T3        | 56             |
|                 | T4        | 1              |
| Clinical N stage| N0        | 22             |
|                 | N1        | 42             |
|                 | N2        | 23             |
|                 | N3        | 5              |
| Clinical M stage| M0        | 71             |
|                 | M1        | 21             |

doi:10.1371/journal.pone.0147372.t001
2.5 Analysis of a cancer cell fraction in an ESCC sample

The cancer cell fraction of an ESCC sample with mutation(s) of the SWI/SNF complex was analyzed by measuring DNA methylation levels of three genomic regions, *TFAP2B*, *ARHGEF4*, and *RAPGEFL1*, which are specifically methylated in ESCC cells [23]. The highest methylation level of the three genomic regions was defined as the cancer cell fraction, as described previously [23]. The eight ESCC samples had cancer cell fractions of 23–87% (mean 54%) (S3 Table).

2.6 Expression analysis

Genome-wide gene expression analysis was conducted using a GeneChip Human Genome U133 Plus 2.0 expression microarray (Affymetrix, Santa Clara, CA), as described previously [25, 26]. Obtained signal intensity of an individual probe was normalized so that mean signal intensity of all the probes would be 500. Mean signal intensity of all the probes in an individual gene was defined as its transcription level, and genes with 250 or more of signal intensities were defined as expressed genes [25].

Gene-specific expression of *ACTL6B* in ESCC cell lines and non-cancerous esophageal tissues was analyzed by quantitative RT-PCR as described previously [25], using primers listed in S2 Table. IMR-32 and KELLY were used as positive controls with *ACTL6B* expression based upon the findings in the Cancer Cell Line Encyclopedia (CCLE) [27].

2.7 Statistical analysis

The association between SWI/SNF alterations, namely SWI/SNF mutations and *ACTL6B* methylation, and tumor characteristics, namely clinical T stage, clinical N stage, and clinical M stage, was evaluated by the Fisher exact test.

Results

3.1 Various components of the SWI/SNF complex were mutated in ESCCs

Ninety-two ESCC samples were analyzed by amplicon sequencing using a bench-top next generation sequencer for 18 genes encoding components of the SWI/SNF complex (mean reading depth = 1,369). Eight of the 92 ESCCs (8.7%) had 11 somatic mutations of 7 genes, *ARID1A*, *ARID2*, *ATRX*, *PBRM1*, *SMARCA4*, *SMARCA1*, and *SMARCC1* (Table 2, Fig 1A and 1B). *SMARCA4* (2 mutations in 2 ESCCs) and *PBRM1* (4 mutations in 2 ESCCs) were mutated in multiple ESCCs, and other genes were mutated in one ESCC. Among these mutations, mutations of *ATRX* (16.3%) and *ARID2* (10.6%) showed low allele frequencies but were able to be successfully detected by deep sequencing (1,191 reads for *ATRX* and 765 reads for *ARID2*). Six of the nine ESCC cell lines had potential somatic mutations for *ARID1A*, *ARID2*, *ATRX*, *PHF10*, *SMARCA1*, and *SMARCA4* (S4 Table).

The somatic mutations were located in various functional domains (Fig 1B). The *SMARCA4* mutations were located in the Forkhead (85Ser>Leu) and SNF2 family N-terminal (882Glu>Lys) domains. The *PBRM1* mutations were located in the bromodomain (80Asn>Ser) and the HMG-box domain (1377Glu>Lys). The presence of these somatic mutations was confirmed by Sanger
sequencing. These results showed that various genes encoding components of the SWI/SNF complex were mutated in ESCCs.

3.2 Somatic mutations were present in most cancer cells in individual ESCCs

To analyze the timing of the somatic mutations of the SWI/SNF complex, a cancer cell fraction was estimated for each of the eight ESCC samples with mutation(s) of the SWI/SNF complex, and the association between the fraction and mutant allele frequency was analyzed. Theoretically, in the case that all the cancer cells in an ESCC sample have a somatic mutation on one allele of a specific gene and allelic imbalance of the region is absent, a mutant allele frequency is expected to be 50% of a cancer cell fraction (Fig 2A). The mutant allele frequency of five of the eight ESCC samples (#85, #89, #94, #127, and #169) was lower than their cancer cell fraction in the same samples, and ranged from 31 to 77% (mean 61%) of the cancer cell fraction (Fig 2B). In contrast, the mutant allele frequency of the other three ESCC samples (#20, #126, and #176) was higher than their cancer cell fraction, and ranged from 107% to 145% (mean 121%) of the cancer cell fraction (Fig 2B). This result showed that most of the cancer cells in some ESCC samples had SWI/SNF mutations on one allele, and suggested that somatic mutations of the SWI/SNF complex are induced at an early stage of esophageal cell carcinogenesis.

3.3 Aberrant DNA methylation of ACTL6B was present in ESCCs

DNA methylation data were available from our previous study for 52 of 92 ESCCs [23]. Eighteen of the 52 ESCCs (34.6%) had aberrant methylation of ACTL6B at its promoter CpG island, but normal esophageal sample and non-cancerous tissue sample did not (Fig 3A). As for the other components of the SWI/SNF complex, ACTL6A, ARID1A, ARID2, PBRM1, SMARCA2, SMARCA4, SMARCAL1, SMARC1, SMARCC2, SMARCD1, SMARCD3, and SMARCE1, none of the 52 ESCCs had their aberrant methylation (Fig 3A).

Three ESCC cell lines, KYSE30, KYSE140, and KYSE220, had a completely methylated ACTL6B promoter (Fig 3C), and ACTL6B was not expressed in these cell lines (Fig 3D). In contrast, two neuroblastoma cell lines, IMR-32 and KELLY, had an unmethylated ACTL6B promoter, and ACTL6B was expressed. These results supported that ACTL6B methylation could be involved in its silencing in tissues where it is expressed.

To assess the role of aberrant DNA methylation of ACTL6B in esophageal squamous cell carcinogenesis, ACTL6B methylation and expression were analyzed in non-cancerous
Fig 1. Somatic mutations of genes encoding the components of the SWI/SNF complex in ESCCs. (A) Status of somatic mutations of the SWI/SNF complex in ESCCs. Somatic mutations were analyzed in the 92
esophageal tissues. ACTL6B was unmethylated, but was not expressed (Fig 3A and 3D). This result suggested that ACTL6B methylation was a passenger in esophageal squamous cell carcinogenesis.

The association between alcohol/smoking exposure and aberrant DNA methylation of ACTL6B was analyzed in non-cancerous esophageal tissues. ACTL6B was not aberrantly methylated in non-cancerous tissues, regardless of alcohol/smoking exposure (Fig 3E).

3.4 SWI/SNF alterations were not associated with characteristics of ESCCs

The association between somatic mutations of the SWI/SNF complex, also ACTL6B methylation, and tumor characteristics was analyzed. Neither somatic mutations of the SWI/SNF complex nor aberrant ACTL6B methylation was associated with clinical T stage, clinical N stage, and clinical M stage (Table 3). This result showed that SWI/SNF alterations were not associated with characteristics of ESCCs.
Fig 3. Aberrant DNA methylation of the components of the SWI/SNF complex in ESCCs. (A) Status of DNA methylation of the SWI/SNF complex in ESCCs. DNA methylation was analyzed in the 52 ESCCs by an Infinium HumanMethylation450 BeadChip array. Among the 52 ESCCs, 18 (34.6%) had aberrant methylation of \(ACTL6B\). The expression level of each gene in non-cancerous esophagus tissues (n = 8, pooled) is shown in the rightmost of the diagram. (B) DNA methylation profile of \(ACTL6B\) across the gene body. (C) DNA methylation at the promoter region of \(ACTL6B\) in ESCC cell lines. (D) \(ACTL6B\) expression level in non-cancerous and ESCC cell lines. (E) \(ACTL6B\) methylation in non-cancerous tissues under the influence of alcohol and smoking.
Components of the SWI/SNF complex, ARID1A, ARID2, ATRX, PBRM1, SMARCA4, SMARCAL1, and SMARCC1, were mutated in ESCCs. Among these, somatic mutations of SMARCAL1 and SMARCC1 were identified for the first time in ESCCs. Somatic mutations with low allele frequencies were successfully detected by deep sequencing. This suggested that deep sequencing focusing on specific sets of genes is useful to detect somatic mutations with low allele frequencies, which are generally difficult to detect by whole-exome sequencing.

Early-stage induction of alterations of the SWI/SNF complex during carcinogenesis has also been suggested for cancers other than ESCCs. During esophageal adenocarcinoma (EAC) development, somatic mutations of ARID1A and SMARCA4 are already present in benign metaplastic never-dysplastic Barrett’s esophagus (NDBE) [28]. During gastric carcinogenesis, aberrant methylation of an ISWI component, SMARCA1, was detected in normal gastric tissues of people infected with Helicobacter pylori [13], a potent gastric cancer inducer. These early induction of genetic and epigenetic alterations of chromatin remodeling factors in multiple types of cancers suggested that their inactivation may be involved in predisposition to cancers (the formation of a field for cancerization [29]).

The mutant allele frequencies of three ESCCs (#20, #126, and #176) were higher than their cancer cell fractions. Theoretically, in the case that all the cancer cells in an ESCC sample have a somatic mutation on one allele of a specific gene and allelic imbalance of the region is absent, a mutant allele frequency is expected to be 50% of a cancer cell fraction (Fig 2A). Therefore, these three ESCCs might have a copy number loss of the wild type allele and this might result in the higher mutant allele frequency than cancer cell fractions.

Aberrant DNA methylation of promoter CpG islands is generally known to cause silencing of their downstream genes [30]. Regarding ACTL6B, aberrant methylation was found in its promoter CpG island, and the island was methylated in ESCCs. Expression analysis in cell

### Table 3. The association between SWI/SNF alterations and clinicopathological characteristics.

| Characteristics | Categories | SWI/SNF mutation | ACTL6B methylation |
|-----------------|------------|------------------|--------------------|
|                 |            | (+) | (-) | P value | (+) | (-) | P value |
| Total           |            | 8   | 84  | 0.71    | 18  | 34  | 0.41   |
| Clinical T stage|            |     |     |         | 6   | 12  |         |
| T1 and T2       |            | 2   | 33  |         | 6   | 12  |         |
| T3 and T4       |            | 6   | 51  |         | 12  | 22  |         |
| Clinical N stage|            | 2   | 20  | 0.38    | 3   | 3   | 0.73   |
| N0              |            |     |     |         | 15  | 31  |         |
| N1, N2, and N3  |            | 6   | 64  |         | 13  | 27  |         |
| Clinical M stage|            | 3   | 18  |         | 5   | 7   |         |
| M0              |            |     |     |         | 5   | 7   |         |
| M1              |            |     |     |         | 3   |     |         |

doi:10.1371/journal.pone.0147372.t003
lines supported that ACTL6B could be silenced by aberrant methylation of its promoter CpG island. At the same time, ACTL6B was not expressed in non-cancerous esophageal tissues, which had an unmethylated ACTL6B promoter. Therefore, ACTL6B methylation was considered to be a passenger in esophageal squamous cell carcinogenesis. In contrast, somatic mutations of other components of the SWI/SNF complex were likely to be drivers because the genes with the mutations were expressed in non-cancerous esophageal tissues (Fig 3A).

Mechanistically, disruption of the SWI/SNF complex has been reported to repress cell growth in other types of cancers [6, 13]. Therefore, it is likely that inactivation of the SWI/SNF complex is involved in esophageal squamous cell carcinogenesis by promoting cell growth rate. At the same time, the SWI/SNF complex is known physiologically to regulate a large number of genes that are involved in a wide variety of cancer-related pathways, including the Wnt pathway, the p53 pathway, the MAPK pathway, DNA repair, cell cycle regulation, and apoptosis [31]. Therefore, complicated combinations of disruption of multiple cancer-related pathways might be alternative mechanisms of esophageal squamous cell carcinogenesis.

In conclusion, genetic and epigenetic alterations of the SWI/SNF complex are present in ESCCs, and genetic alterations were suggested to have been induced at an early stage of esophageal squamous cell carcinogenesis.

Supporting Information
S1 Table. Primers used for Sanger sequencing.
(XLSX)

S2 Table. Primers used for DNA methylation analysis and expression analysis.
(XLSX)

S3 Table. Cancer cell fractions in the 8 ESCC samples with mutations of chromatin remodelers.
(XLSX)

S4 Table. Potential somatic mutations detected in the 9 ESCC cell lines.
(XLSX)

Acknowledgments
We thank Ms. Reiko Nagano for supporting the mutation analysis.

Author Contributions
Conceived and designed the experiments: HN HT TU. Performed the experiments: HN HT TK EK NH SY. Analyzed the data: HN HT SY TU. Contributed reagents/materials/analysis tools: HN HT TN SY HI YT YK. Wrote the paper: HN HT TU.

References
1. Baba Y, Ishimoto T, Harada K, Kosumi K, Murata A, Miyake K, et al. Molecular Characteristics of Basaloid Squamous Cell Carcinoma of the Esophagus: Analysis of KRAS, BRAF, and PIK3CA Mutations and LINE-1 Methylation. Ann Surg Oncol. Online. Epub 2015/02/19. doi:10.1245/s10434-015-4445-z PMID: 25691283.

2. Gao YB, Chen ZL, Li JG, Hu XD, Shi XJ, Sun ZM, et al. Genetic landscape of esophageal squamous cell carcinoma. Nat Genet. 2014; 46(10):1097–102. Epub 2014/08/26. [pii] doi:10.1038/ng.3076 PMID: 25151357.

3. Lin DC, Hao JJ, Nagata Y, Xu L, Shang L, Meng X, et al. Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat Genet. 2014; 46(5):467–73. Epub 2014/04/02. [pii] doi:10.1038/ng.2935 PMID: 24686850.
4. Wang K, Kan J, Yuen ST, Shi ST, Chu KM, Law S, et al. Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat Genet. 2011; 43(12):1219–23. PMID: 22037554. doi: 10.1038/ng.982

5. Yoda Y, Takeshima H, Niwa T, Kim JG, Ando T, Kushima R, et al. Integrated analysis of cancer-related pathways affected by genetic and epigenetic alterations in gastric cancer. Gastric Cancer. 2015; 18(1):65–76. Epub 2014/02/11. doi: 10.1007/s10120-014-0348-0 PMID: 24510342.

6. Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, Tao J, et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet. 2012; 44(5):570–4. PMID: 22484628. doi: 10.1038/ng.2246

7. Wang X, Haswell JR, Roberts CW. Molecular pathways: SWI/SNF (BAF) complexes are frequently mutated in cancer—mechanisms and potential therapeutic insights. Clin Cancer Res. 2014; 20(1):21–7. Epub 2013/10/15. [pii] doi: 10.1158/1078-0432.CCR-13-0280 PMID: 24122795.

8. Wilson BG, Roberts CW. SWI/SNF nucleosome remodellers and cancer. Nat Rev Cancer. 2011; 11(7):481–92. Epub 2011/06/10. [pii] doi: 10.1038/nrc3068 PMID: 21654818.

9. Jones S, Wang TL, Shih ie M, Mao TL, Nakayama K, Roden R, et al. Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma. Science. 2010; 330(6001):228–31. Epub 2010/09/10. [pii] doi: 10.1126/science.1196333 PMID: 20826764.

10. Wiegand KC, Shah SP, Al-Agha OM, Zhao Y, Tse K, Zeng T, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010; 363(16):1532–43. Epub 2010/10/15. doi: 10.1056/NEJMoa1008433 PMID: 20942669.

11. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, et al. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet. 2012; 44(7):760–4. Epub 2012/05/29. [pii] doi: 10.1038/ng.2291 PMID: 22634756.

12. Huang J, Deng Q, Wang Q, Li KY, Dai JH, Li N, et al. Exome sequencing of hepatitis B virus-associated hepatocellular carcinoma. Nat Genet. 2012; 44(10):1117–21. Epub 2012/08/28. [pii] doi: 10.1038/ng.2391 PMID: 22922871.

13. Takeshima H, Niwa T, Takahashi T, Wakabayashi M, Yamashita S, Ando T, et al. Frequent involvement of chromatin remodeler alterations in gastric field cancerization. Cancer Lett. 2015; 357(1):328–38. Epub 2014/12/03. [pii] doi: S0304-3835(14)00709-5 [pii] doi: 10.1016/j.canlet.2014.11.038 PMID: 25462860.

14. Li M, Zhao H, Zhang X, Wood LD, Anders RA, Choti MA, et al. Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet. 2011; 43(9):828–31. Epub 2011/08/09. [pii] doi: 10.1038/ng.903 PMID: 21822264.

15. Varela I, Tarpey P, Raine K, Huang D, Ong CK, Stephens P, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature. 2011; 469(7331):539–42. Epub 2011/01/21. [pii] doi: 10.1038/nature09639 PMID: 21248752.

16. Jelincic P, Mueller JJ, Olvera N, Dao F, Scott SN, Shah R, et al. Recurrent SMARCA4 mutations in small cell carcinoma of the ovary. Nat Genet. 2014; 46(5):424–6. Epub 2014/03/25. [pii] doi: 10.1038/ng.2922 PMID: 24658004.

17. Ramos P, Kamezis AN, Craig DW, Sekulic A, Russell ML, Hendricks WP, et al. Small cell carcinoma of the ovary, hypercalcaemic type, displays frequent inactivating germline and somatic mutations in SMARCA4. Nat Genet. 2014; 46(5):427–9. Epub 2014/03/25. [pii] doi: 10.1038/ng.2928 PMID: 24658001.

18. Witkowski L, Carrot-Zhang J, Albrecht S, Fahiminiya S, Hamel N, Tomlai E, et al. Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcaemic type. Nat Genet. 2014; 46(5):438–43. Epub 2014/03/25. [pii] doi: 10.1038/ng.2931 PMID: 24658002.

19. Zhang X, Sun Q, Shan M, Niu M, Liu T, Xia B, et al. Promoter hypermethylation of ARID1A gene is responsible for its low mRNA expression in many invasive breast cancers. PLoS One. 2013; 8(1):e53931. Epub 2013/01/26. doi: 10.1371/journal.pone.0053931 PMID: 23349767.

20. Khursheed M, Kolla JN, Kotapalli V, Gupta N, Gowrishankar S, Uppin SG, et al. ARID1B, a member of the human SWI/SNF chromatin remodeling complex, exhibits tumour-suppressor activities in pancreatic cancer cell lines. Br J Cancer. 2013; 108(10):2056–62. Epub 2013/05/11. [pii] doi: 10.1038/bjc.2013.200 PMID: 23660946.

21. Revill K, Wang T, Lachenmayer A, Kojima K, Harrington A, Li J, et al. Genome-wide methylation analysis and epigenetic unmasking identify tumor suppressor genes in hepatocellular carcinoma. Gastroenterology. 2013; 145(6):1424–35 e1-25. Epub 2013/09/10. doi: S0016-5085(13)01275-4 [pii] doi: 10.1053/j.gastro.2013.08.055 PMID: 24012984.
22. Shimada Y, Imamura M, Wagata T, Yamaguchi N, Tobe T. Characterization of 21 newly established esophageal cancer cell lines. Cancer. 1992; 69(2):277–84. Epub 1992/01/15. PMID:1728357.

23. Takahashi T, Matsuda Y, Yamashita S, Hattori N, Kushima R, Lee YC, et al. Estimation of the fraction of cancer cells in a tumor DNA sample using DNA methylation. PLoS One. 2013; 8(12):e82302. Epub 2013/12/07. doi: 10.1371/journal.pone.0082302 PONE-D-13-23494 [pii]. PMID:24312652.

24. Asada K, Ando T, Niwa T, Nanjo S, Watanabe N, Okochi-Takada E, et al. FHL1 on chromosome X is a single-hit gastrointestinal tumor-suppressor gene and contributes to the formation of an epigenetic field defect. Oncogene. 2013; 32(17):2140–9. Epub 2012/06/13. [pii] doi:10.1038/onc.2012.228 PMID:22689052.

25. Takeshima H, Yamashita S, Shimazu T, Niwa T, Ushijima T. The presence of RNA polymerase II, active or stalled, predicts epigenetic fate of promoter CpG islands. Genome Res. 2009; 19(11):1974–82. Epub 2009/08/05. [pii] doi:10.1101/gr.093310.109 PMID:19652013.

26. Takeshima H, Yamashita S, Shimazu T, Ushijima T. Effects of genome architecture and epigenetic factors on susceptibility of promoter CpG islands to aberrant DNA methylation induction. Genomics. 2011; 98(3):182–8. Epub 2011/06/21. doi: S0888-7543(11)00140-6 [pii] doi: 10.1016/j.ygeno.2011.06.003 PMID:21683780.

27. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483 (7391):603–7. Epub 2012/03/31. [pii] doi:10.1038/nature11003 PMID:22460905.

28. Weaver JM, Ross-Innes CS, Shannon N, Lynch AG, Forshaw T, Barbera M, et al. Ordering of mutations in preinvasive disease stages of esophageal carcinogenesis. Nat Genet. 2014; 46(8):837–43. Epub 2014/06/24. [pii] doi:10.1038/ng.3013 PMID:24952744.

29. Ushijima T, Hattori N. Molecular pathways: involvement of Helicobacter pylori-triggered inflammation in the formation of an epigenetic field defect, and its usefulness as cancer risk and exposure markers. Clin Cancer Res. 2012; 18(4):923–9. Epub 2011/12/30. doi:10.1158/1078-0432.CCR-11-2011 PMID:22205889.

30. Lin JC, Jeong S, Liang G, Takai D, Fatemi M, Tsai YC, et al. Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Cancer Cell. 2007; 12(5):432–44. Epub 2007/11/13. doi: S1535-6108(07)00299-1 [pii] doi:10.1016/j.ccr.2007.10.014 PMID:17996647.

31. Euskirchen GM, Auerbach RK, Davidov E, Gianoulis TA, Zhong G, Rozowsky J, et al. Diverse roles and interactions of the SWI/SNF chromatin remodeling complex revealed using global approaches. PLoS Genet. 2011; 7(3):e1002008. Epub 2011/03/17. doi:10.1371/journal.pgen.1002008 PMID:21408204.